Clinical trial: Lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects

D. A. Peura, D. S. Riff, A. M. Snoddy, M (Brian) Fennerty

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms. Aim To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn. Methods A total of 864 subjects with heartburn on ≥2 days-week over the past month were randomized to double-blind treatment with lansoprazole 15 or 30 mg or placebo each morning. Endpoints were percentage of nighttimes without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Results Mean percentage of nighttimes without heartburn was significantly greater with lansoprazole 15 mg (61.3%) or lansoprazole 30 mg (61.7%) vs. placebo (47.8%) over 14 days (P <0.0001 vs. placebo for both doses). Percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1 were significantly greater with lansoprazole 15 or 30 mg vs. placebo. Conclusions Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. The benefit of therapy on 24-h heartburn and nighttime heartburn on day 1 of treatment was also evident. Lansoprazole 15 mg is a suitable choice for management of frequent nighttime heartburn.

Original languageEnglish (US)
Pages (from-to)459-468
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume30
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Lansoprazole
Heartburn
Placebos
Clinical Trials
Therapeutics
Esophageal Diseases
Gastroesophageal Reflux

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical trial : Lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. / Peura, D. A.; Riff, D. S.; Snoddy, A. M.; Fennerty, M (Brian).

In: Alimentary Pharmacology and Therapeutics, Vol. 30, No. 5, 09.2009, p. 459-468.

Research output: Contribution to journalArticle

@article{140f6e6d22334c43b7366cfe9ba5ae7b,
title = "Clinical trial: Lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects",
abstract = "Background Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms. Aim To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn. Methods A total of 864 subjects with heartburn on ≥2 days-week over the past month were randomized to double-blind treatment with lansoprazole 15 or 30 mg or placebo each morning. Endpoints were percentage of nighttimes without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Results Mean percentage of nighttimes without heartburn was significantly greater with lansoprazole 15 mg (61.3{\%}) or lansoprazole 30 mg (61.7{\%}) vs. placebo (47.8{\%}) over 14 days (P <0.0001 vs. placebo for both doses). Percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1 were significantly greater with lansoprazole 15 or 30 mg vs. placebo. Conclusions Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. The benefit of therapy on 24-h heartburn and nighttime heartburn on day 1 of treatment was also evident. Lansoprazole 15 mg is a suitable choice for management of frequent nighttime heartburn.",
author = "Peura, {D. A.} and Riff, {D. S.} and Snoddy, {A. M.} and Fennerty, {M (Brian)}",
year = "2009",
month = "9",
doi = "10.1111/j.1365-2036.2009.04064.x",
language = "English (US)",
volume = "30",
pages = "459--468",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Clinical trial

T2 - Lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects

AU - Peura, D. A.

AU - Riff, D. S.

AU - Snoddy, A. M.

AU - Fennerty, M (Brian)

PY - 2009/9

Y1 - 2009/9

N2 - Background Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms. Aim To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn. Methods A total of 864 subjects with heartburn on ≥2 days-week over the past month were randomized to double-blind treatment with lansoprazole 15 or 30 mg or placebo each morning. Endpoints were percentage of nighttimes without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Results Mean percentage of nighttimes without heartburn was significantly greater with lansoprazole 15 mg (61.3%) or lansoprazole 30 mg (61.7%) vs. placebo (47.8%) over 14 days (P <0.0001 vs. placebo for both doses). Percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1 were significantly greater with lansoprazole 15 or 30 mg vs. placebo. Conclusions Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. The benefit of therapy on 24-h heartburn and nighttime heartburn on day 1 of treatment was also evident. Lansoprazole 15 mg is a suitable choice for management of frequent nighttime heartburn.

AB - Background Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms. Aim To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn. Methods A total of 864 subjects with heartburn on ≥2 days-week over the past month were randomized to double-blind treatment with lansoprazole 15 or 30 mg or placebo each morning. Endpoints were percentage of nighttimes without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Results Mean percentage of nighttimes without heartburn was significantly greater with lansoprazole 15 mg (61.3%) or lansoprazole 30 mg (61.7%) vs. placebo (47.8%) over 14 days (P <0.0001 vs. placebo for both doses). Percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1 were significantly greater with lansoprazole 15 or 30 mg vs. placebo. Conclusions Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. The benefit of therapy on 24-h heartburn and nighttime heartburn on day 1 of treatment was also evident. Lansoprazole 15 mg is a suitable choice for management of frequent nighttime heartburn.

UR - http://www.scopus.com/inward/record.url?scp=68149111568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149111568&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2009.04064.x

DO - 10.1111/j.1365-2036.2009.04064.x

M3 - Article

C2 - 19523177

AN - SCOPUS:68149111568

VL - 30

SP - 459

EP - 468

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -